- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 27, 2023
Highlights
- Year Range
- $0.01 - $0.08
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RCKTW Performance Chart
Rocket Pharmaceuticals Inc. Warrant (RCKTW) is down 60.5% since the beginning of the year. At $0 per share, RCKTW is trading 88.6% below its 52-week high of $0.
Loading charts...
Returns By Period
Rocket Pharmaceuticals Inc. Warrant (RCKTW) has returned -60.49% so far this year and -65.09% over the past 12 months.
Rocket Pharmaceuticals Inc. Warrant
- 1D
- 0.00%
- 1M
- -3.03%
- YTD
- -60.49%
- 6M
- -71.34%
- 1Y
- -65.09%
- 3Y*
- -67.51%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
RCKTW Monthly Returns History
Based on dividend-adjusted daily data since Feb 27, 2023, RCKTW's average daily return is +0.80%, while the average monthly return is +2.80%. At this rate, an investment would double in approximately 2.1 years.
Historically, 37% of months were positive and 63% were negative. The best month was Nov 2023 with a return of +250.0%, while the worst month was Apr 2024 at -69.0%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 5 months.
On a daily basis, RCKTW closed higher 32% of trading days. The best single day was Sep 20, 2023 with a return of +245.3%, while the worst single day was Dec 19, 2025 at -48.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -34.57% | 78.62% | -27.46% | -51.94% | -2.02% | -1.03% | -60.49% | ||||||
| 2025 | 127.11% | -19.09% | -25.43% | 27.66% | -48.33% | 27.10% | -0.53% | 1.81% | -1.75% | -4.08% | -0.27% | -35.20% | -29.15% |
| 2024 | -48.96% | 3.96% | 15.08% | -68.98% | 29.09% | -49.33% | 15.32% | 14.29% | -12.50% | 7.86% | -50.33% | -8.53% | -93.00% |
| 2023 | -20.00% | -31.92% | -13.53% | 98.16% | -32.14% | -10.53% | -41.76% | 71.72% | -29.41% | 250.00% | 16.67% | 63.33% |
Benchmark Metrics
Rocket Pharmaceuticals Inc. Warrant has an annualized alpha of 684.78%, beta of -0.26, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 28, 2023.
- This stock participated in 345.23% of S&P 500 Index downside but only -81.83% of its upside - more exposed to losses than it benefited from rallies.
- Beta of -0.26 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 684.78%
- Beta
- -0.26
- R²
- 0.00
- Upside Capture
- -81.83%
- Downside Capture
- 345.23%
Return for Risk
Risk / Return Rank
RCKTW ranks 29 for risk / return — below 29% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Rocket Pharmaceuticals Inc. Warrant (RCKTW) and compare them to S&P 500 Index.
| RCKTW | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.33 | 2.39 | -2.72 |
Sortino ratioReturn per unit of downside risk | 0.69 | 3.25 | -2.57 |
Omega ratioGain probability vs. loss probability | 1.10 | 1.43 | -0.34 |
Calmar ratioReturn relative to maximum drawdown | -0.76 | 3.11 | -3.88 |
Martin ratioReturn relative to average drawdown | -1.17 | 14.38 | -15.55 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Rocket Pharmaceuticals Inc. Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Rocket Pharmaceuticals Inc. Warrant was 98.26%, occurring on May 22, 2026. The portfolio has not yet recovered.
The current Rocket Pharmaceuticals Inc. Warrant drawdown is 98.08%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -98.26%May 2026 | 2y 4mo | — | 2y 5moDec 2023 - now |
2023 bear market2023 | -79.93%Aug 2023 | 5mo 23d | 28d | 6mo 21dMar 2023 - Sep 2023 |
2023 bear market2023 | -76.30%Oct 2023 | 28d | 1mo 11d | 2mo 9dSep 2023 - Nov 2023 |
2023 bear market2023 | -28.24%Dec 2023 | 0s | 14d | 14dDec 2023 - Dec 2023 |
2023 bear market2023 | -20.00%Feb 2023 | 0s | 2d | 2dFeb 2023 - Mar 2023 |
Drawdown Indicators
| RCKTW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.26% | -56.78% | -41.48% |
Max Drawdown (1Y)Largest decline over 1 year | -85.97% | -9.10% | -76.87% |
Max Drawdown (3Y)Largest decline over 3 years | -98.26% | -18.90% | -79.36% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.08% | 0.00% | -98.08% |
Average DrawdownAverage peak-to-trough decline | -72.58% | -10.72% | -61.86% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.95% | 1.97% | +53.98% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Rocket Pharmaceuticals Inc. Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Rocket Pharmaceuticals Inc. Warrant is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RCKTW
Add Rocket Pharmaceuticals Inc. Warrant to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RCKTW